Navigation Links
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
Date:8/30/2007

WASHINGTON, Aug. 30 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held biotechnology company, today announced that it has hired Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer.

Dr. Stogniew will be responsible for Prestwick's pre-clinical development, regulatory and patent activities around its portfolio of products including its lead product candidate, tetrabenazine, a highly selective and reversible dopamine depletor in Phase 3 clinical trials for potential use as a treatment for chorea associated with Huntington's Disease.

He joins Prestwick most recently from Zelos Therapeutics, where he was Executive Vice President of Development responsible for pre-clinical, regulatory and patent development.

"With 25 years focused on developing drugs and 25 patents to his name, Marty will immediately help Prestwick as we work to execute and enhance our pipeline," said George F. Horner III, President and Chief Executive Officer of Prestwick. "He has made a significant impact in the development of successful drugs such as Anidulafugin, Amifostine and Idarubicin -- all of which are now on the market and positively impacting patients' lives."

Dr. Stogniew worked with Mr. Horner at Vicuron Pharmaceuticals, Inc. as Executive Vice President of Scientific Affairs from 2001 to 2005 before Vicuron was purchased by Pfizer in 2005 for $1.9 billion. Prior to Vicuron, Dr. Stogniew served as Chief Scientific Officer at Next Pharmaceuticals, Inc. and as Vice President of Pharmaceutical Sciences at MedImmune. Dr. Stogniew holds a Ph.D. in Medicinal Chemistry and a B.S. in Pharmacy from the University of Maryland.

About Prestwick

Prestwick is currently managing a portfolio of pipeline product candidates being studied for CNS conditions with significant unmet needs, including Huntington's disease, Parkinson's disease, restless legs syndrome, schizophrenia, autism, Alzheimer's disease and sleep apnea.

Please go to http://www.prestwickpharma.com for more information.


'/>"/>
SOURCE Prestwick Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Traveling stem cell show continues state tour
2. AT&T - BellSouth merger: Revestiture continues
3. Madison biotech continues its climb
4. Brady continues growth through Asian acquisition
5. Transition continues to impact Third Wave financials
6. Line between big pharma, big biotech continues to blur
7. Wisconsin giant continues to dominate the health care IT market
8. API Software continues expansion
9. Third Wave continues molecular diagnostic focus with new CEO
10. Midwest Public-Sector Biotech Continues to Sizzle
11. Corona Optical Systems continues to excite investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
Breaking Biology News(10 mins):